文献速递浆细胞疾病造血干细胞移植与细胞治疗

Talquetamab 治疗复发或难治性多发性骨髓瘤患者的疗效与安全性(MonumenTAL-1):一项多中心、开放标签、1-2 期研究

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.
PubMed 文献 · Lancet Haematol · 2025-03-13

MonumenTAL-1 是一项多中心、开放标签、1-2 期研究,评估皮下注射 talquetamab 0·4 mg/kg 每周一次和 0·8 mg/kg 每两周一次推荐剂量在复发或难治性多发性骨髓瘤患者中的安全性与活性。截至 2023 年 10 月 11 日,375 例患者接受推荐剂量治疗,总体缓解率分别为 74%、69% 和 67%(既往 T 细胞重定向治疗组)。最常见不良事件为细胞因子释放综合征、味觉改变和感染,致死性不良事件均与治疗无关。

要点

  • 0·4 mg/kg 每周一次组总体缓解率为 74%(106/143,95% CI 66-81)。
  • 0·8 mg/kg 每两周一次组总体缓解率为 69%(107/154,95% CI 62-77)。
  • 既往 T 细胞重定向治疗组总体缓解率为 67%(52/78,95% CI 55-77)。

核心结论

  • Talquetamab 在重度经治的复发或难治性多发性骨髓瘤患者中持续显示高总体缓解率。
  • 在既往接受过 T 细胞重定向治疗(包括靶向 BCMA 的治疗)的患者中,总体缓解率仍有前景。
  • 靶向、脱肿瘤的不良事件常见,但导致治疗中断的情况较少。

研究设计与样本

  • MonumenTAL-1 是一项多中心、开放标签、1-2 期研究,1 期结果已先前发表。
  • 1 期确定的皮下推荐剂量为 talquetamab 0·4 mg/kg 每周一次和 0·8 mg/kg 每两周一次,并在 2 期患者中评估。
  • 纳入标准为年龄 18 岁及以上、既往至少三线治疗、ECOG 体能状态 0 至 2、未接受或曾接受 T 细胞重定向治疗。
  • 主要终点为独立评审委员会评估的总体缓解率,在所有接受至少一剂 talquetamab 的患者中评估。
  • 研究注册号为 ClinicalTrials.gov NCT03399799(1 期)和 NCT04634552(2 期)。

主要发现

  • 2018 年 1 月 3 日至 2023 年 2 月 20 日,所有 1-2 期队列共筛查 735 例患者,其中 537 例接受治疗,198 例(27%)被排除,最常见原因为不符合入选标准或无可测量病灶。
  • 截至 2023 年 10 月 11 日,375 例患者接受推荐剂量 talquetamab 治疗,分为三组:143 例(0·4 mg/kg 每周一次组)和 154 例(0·8 mg/kg 每两周一次组)为未接受 T 细胞重定向治疗患者,78 例为既往接受 T 细胞重定向治疗并接受任一推荐剂量的患者(既往 T 细胞重定向治疗组)。
  • 375 例患者中 217 例(58%)为男性,158 例(42%)为女性;325 例(87%)为白人,32 例(9%)为黑人。
  • 中位随访时间:0·4 mg/kg 每周一次组为 25·6 个月(IQR 8·5-25·9),0·8 mg/kg 每两周一次组为 19·4 个月(IQR 9·2-20·7),既往 T 细胞重定向治疗组为 16·8 个月(IQR 7·6-18·7)。
  • 总体缓解率:0·4 mg/kg 每周一次组为 74%(106/143,95% CI 66-81),0·8 mg/kg 每两周一次组为 69%(107/154,95% CI 62-77),既往 T 细胞重定向治疗组为 67%(52/78,95% CI 55-77)。

关键数值与推荐

  • 总体缓解率(独立评审委员会评估):0·4 mg/kg 每周一次组 74%(106/143,95% CI 66-81)。
  • 总体缓解率(独立评审委员会评估):0·8 mg/kg 每两周一次组 69%(107/154,95% CI 62-77)。
  • 总体缓解率(独立评审委员会评估):既往 T 细胞重定向治疗组 67%(52/78,95% CI 55-77)。
  • 常见不良事件(0·4 mg/kg 每周一次组、0·8 mg/kg 每两周一次组、既往 T 细胞重定向治疗组):细胞因子释放综合征分别为 113/143(79%)、115/154(75%)、57/78(73%);味觉改变分别为 103/143(72%)、110/154(71%)、59/78(76%);感染分别为 85/143(59%)、105/154(68%)、59/78(76%)。
  • 常见 3-4 级不良事件(0·4 mg/kg 每周一次组、0·8 mg/kg 每两周一次组、既往 T 细胞重定向治疗组):中性粒细胞减少分别为 44/143(31%)、33/154(21%)、37/78(47%);贫血分别为 45/143(31%)、40/154(26%)、21/78(27%);淋巴细胞减少分别为 37/143(26%)、40/154(26%)、13/78(17%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Talquetamab is the first GPRC5D × CD3 bispecific antibody approved for relapsed or refractory multiple myeloma. In phase 1 of the MonumenTAL-1 study, initial results of subcutaneous talquetamab 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks showed preliminary clinical activity. We describe safety and activity results in patients treated with talquetamab, including patients who had received previous T-cell redirection therapy (TCR). This post-hoc analysis was done with more mature median follow-up to evaluate duration of response in patients treated with talquetamab 0·8 mg/kg every 2 weeks. METHODS: MonumenTAL-1 is a multicentre, open-label, phase 1-2 study of talquetamab, phase 1 of which has previously been published. The 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks recommended subcutaneous doses identified in phase 1 were evaluated in phase 2 in patients who were 18 years of age or older, had at least three previous lines of therapy, had an Eastern Cooperative Oncology Group performance status of 0 to 2, and were naive or exposed to previous TCR. The primary endpoint was overall response rate assessed by independent review committee in all patients who received at least one dose of talquetamab. Safety was assessed in all patients who received at least one dose of talquetamab. This study was registered with ClinicalTrials.gov, NCT03399799 (phase 1) and NCT04634552 (phase 2). FINDINGS: Between Jan 3, 2018, and Feb 20, 2023, 735 patients were screened across all phase 1-2 cohorts. Of these, 537 patients screened for inclusion were treated across phase 1 and 2 cohorts, of whom 198 (27%) patients were excluded from the study, most commonly due to not meeting eligibility criteria or not having measurable disease. As of Oct 11, 2023, 375 patients had received recommended talquetamab doses across three groups: 143 (0·4 mg/kg once a week group) and 154 (0·8 mg/kg every 2 weeks group) TCR-naive patients and 78 with previous TCR who received either recommended dose (previous TCR group). 217 (58%) of 375 patients were male and 158 (42%) were female. 325 (87%) of 375 patients were White and 32 (9%) patients were Black. Median follow-up was 25·6 months (IQR 8·5-25·9) in the 0·4 mg/kg once a week group, 19·4 months (9·2-20·7) in the 0·8 mg/kg every 2 weeks group, and 16·8 months (7·6-18·7) in the previous TCR group. Overall response rate was 74% (106 of 143 patients, 95% CI 66-81) in the 0·4 mg/kg once a week group, 69% (107 of 154 patients, 62-77) in the 0·8 mg/kg every 2 weeks group, and 67% (52 of 78 patients, 55-77) in the previous TCR group. Most common adverse events in the 0·4 mg/kg once a week, 0·8 mg/kg every 2 weeks, and previous TCR groups were cytokine release syndrome (113 [79%] of 143 patients, 115 [75%] of 154 patients, and 57 [73%] of 78 patients), taste changes (103 [72%], 110 [71%], and 59 [76%]), and infections (85 [59%], 105 [68%], and 59 [76%]). Most common grade 3-4 adverse events were neutropenia (44 [31%], 33 [21%], and 37 [47%]), anaemia (45 [31%], 40 [26%], and 21 [27%]), and lymphopenia (37 [26%], 40 [26%], and 13 [17%]). Fatal adverse events occurred in five patients in the 0·4 mg/kg once a week group, seven patients in the 0·8 mg/kg every 2 weeks group, and no patients in the previous TCR group; none were related to treatment. INTERPRETATION: Talquetamab continued to demonstrate high overall response rates in heavily pretreated patients with relapsed or refractory multiple myeloma with longer follow-up in this post-hoc analysis. Overall response rate was promising in patients with previous TCR, including therapies targeting BCMA. On-target, off-tumour adverse events were common but led to few treatment discontinuations. FUNDING: Janssen.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Chari A, Touzeau C, Schinke C, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025. PMID: 40090350. doi:10.1016/S2352-3026(24)00385-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。